Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWZIRJ)

• Drug Name: LY404039 Drug Info
• Synonyms: LY 404039; LY-404039; (1R,2S,5R,6R)-2-amino-4,4-dioxo-4$l^{6}-thiabicyclo[3.1.0]hexane-2,6-dicarboxylic Acid; 4-amino-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9834591
  ChEBI ID: CHEBI:94640
  CAS Number: CAS 635318-11-5
  TTD Drug ID: DMWZIRJ

Molecule-Related Drug Atlas

Drug(s) Targeting Metabotropic glutamate receptor 3 (mGluR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-4995819	DMNTC7O	Major depressive disorder	6A70.3	Phase 2	[5]
Oleoyl-estrone	DM0RA8F	Alzheimer disease	8A20	Phase 2	[6]
MP-101	DMYCITZ	Alzheimer disease	8A20	Phase 2	[7]
BCI-838	DMRXDN3	Major depressive disorder	6A70.3	Phase 1	[8]
Pomaglumetad	DMTOLI5	Schizophrenia	6A20	Phase 1	[9]
BCI-632	DMZYCWT	Alzheimer disease	8A20	Phase 1	[10]
PMID25435285-Compound-16	DMKFX2G	N. A.	N. A.	Patented	[11]
PMID25435285-Compound-15	DMHBWNS	N. A.	N. A.	Patented	[11]
PMID25435285-Compound-20	DMG9FYH	N. A.	N. A.	Patented	[11]
PMID25435285-Compound-22	DM27U1F	N. A.	N. A.	Patented	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Metabotropic glutamate receptor 3 (mGluR3)	TT8A9EF	GRM3_HUMAN	Agonist	[2] , [3] , [4]

References

• [1] ClinicalTrials.gov (NCT01487083) A Long-Term Study in Schizophrenia. U.S. National Institutes of Health.
• [2] Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75.
• [3] Glutamate and dopamine components in schizophrenia. J Psychiatry Neurosci. 2009 Mar;34(2):143-9.
• [4] Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse. 2009 Mar;63(3):247-51.
• [5] Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health.
• [8] Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010
• [9] LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45.
• [10] Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87.
• [11] Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90.